Patient-Reported Health-Related Quality of Life Impact and Symptom Severity in Patients with Lyme Borreliosis in the Burden of Lyme Disease (BOLD) Study

Lyme borreliosis (LB) can manifest as a localized infection or, if left untreated, disseminated disease. This analysis used Patient-Reported Outcome tools to assess general health, fatigue, pain, and cognitive function in patients with localized or disseminated LB, compared with age- and site-matched controls without LB. All participants were enrolled in the Burden of Lyme Disease (BOLD) study; LB cases were assessed at 3 time points: the enrollment visit, and two follow-up visits conducted within 10 months of enrollment. Controls were evaluated at 2 time points: the enrollment contact and a follow-up contact 16–18 months post-enrollment. Symptom severity and general health quality between groups were compared using two-tailed Student’s t-tests and multivariate regression analyses. Disseminated LB cases reported greater fatigue and pain than localized LB (disseminated LB fatigue scores: 4.1, 3.7, and 3.5 at Visits 1, 2, and 3, respectively vs. localized LB: 2.9, 3.0, and 2.9; disseminated LB pain scores: 2.5, 1.6, and 1.3 vs. localized LB: 0.9, 0.6, and 0.8) and controls (fatigue score: 3.2; pain score: 1.0). Disseminated LB was also associated with reduced health-related quality of life. The results of this study indicate that health-related quality of life may vary by disease stage and that patients with disseminated disease showed persistent impairment during the acute phase and at 10-month follow-up.

Authors

Institutions

Publication Details

Journal
Pathogens
Published
2026-07-02
DOI
https://doi.org/10.3390/pathogens15070701
Primary Topic
Vector-borne infectious diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patient-Reported Health-Related Quality of Life Impact and Symptom Severity in Patients with Lyme Borreliosis in the Burden of Lyme Disease (BOLD) Study

Johan Berglund, Franc Strle, James H. Stark, Alexandra Loew-Baselli et al.
Pathogens
Vector-borne infectious diseases
article

Patient-Reported Health-Related Quality of Life Impact and Symptom Severity in Patients with Lyme Borreliosis in the Burden of Lyme Disease (BOLD) Study

Johan Berglund, Franc Strle, James H. Stark, Alexandra Loew-Baselli, Holly Yu, Anna Moniuszko‐Malinowska, Amanda R. Mercadante, Juanita Edwards, Ye Tan, Kate Halsby, Mendwas Dzingina, on behalf of the BOLD Study Group, Elizabeth Begier, Frederick J. Angulo
article en

Abstract

Lyme borreliosis (LB) can manifest as a localized infection or, if left untreated, disseminated disease. This analysis used Patient-Reported Outcome tools to assess general health, fatigue, pain, and cognitive function in patients with localized or disseminated LB, compared with age- and site-matched controls without LB. All participants were enrolled in the Burden of Lyme Disease (BOLD) study; LB cases were assessed at 3 time points: the enrollment visit, and two follow-up visits conducted within 10 months of enrollment. Controls were evaluated at 2 time points: the enrollment contact and a follow-up contact 16–18 months post-enrollment. Symptom severity and general health quality between groups were compared using two-tailed Student’s t-tests and multivariate regression analyses. Disseminated LB cases reported greater fatigue and pain than localized LB (disseminated LB fatigue scores: 4.1, 3.7, and 3.5 at Visits 1, 2, and 3, respectively vs. localized LB: 2.9, 3.0, and 2.9; disseminated LB pain scores: 2.5, 1.6, and 1.3 vs. localized LB: 0.9, 0.6, and 0.8) and controls (fatigue score: 3.2; pain score: 1.0). Disseminated LB was also associated with reduced health-related quality of life. The results of this study indicate that health-related quality of life may vary by disease stage and that patients with disseminated disease showed persistent impairment during the acute phase and at 10-month follow-up.

PathogensVol. 15(7)
Medical University of Białystok (PL), Pfizer (United States) (US), Pfizer (United Kingdom) (GB), Ljubljana University Medical Centre (SI), Pfizer (Austria) (AT), Pfizer (Ireland) (IE), Blekinge Institute of Technology (SE)
Openalex Percentile: Top 7%
Vector-borne infectious diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.